Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Sunoco Q4 Sales $4.95B Beat $4.60B Estimate, Adj. EBITDA $198M Vs. $159M YoY, Net Income $100M Vs. $83M YoY
Sunoco (NYSE:SUN) reported quarterly sales of $4.95 billion which beat the analyst consensus estimate of $4.60 billion by 7.70 percent. This is a 94.05 percent increase over sales of $2.55 billion the same period last
Earnings Scheduled For February 16, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.
Citigroup Downgrades Sunoco to Neutral, Raises Price Target to $49
Citigroup analyst Timm Schneider downgrades Sunoco (NYSE:SUN) from Buy to Neutral and raises the price target from $44 to $49.
Where Sunoco Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Sunoco (NYSE:SUN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
